Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Aug 21, 2019 7:59 AM EDT

News Releases

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

July 17, 2019

FOSTER CITY, Calif. , July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price

Mirum Pharmaceuticals Initiates Phase 3 Clinical Trial for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

July 9, 2019

First patient dosed in Phase 3 trial evaluating efficacy and safety of maralixibat Topline results expected in fourth quarter of 2020 FOSTER CITY, Calif. , July 9, 2019 /PRNewswire/ -- Mirum Pharmaceuticals today announced the dosing of the first patient in the Phase 3 MARCH-PFIC clinical trial of

Mirum Pharmaceuticals Presents New Data Demonstrating Durable Improvements in Clinical Outcome Measures in Patients with PFIC2 and Alagille Syndrome Treated with Maralixibat

April 15, 2019

Late breaker presentation of long-term analysis of Phase 2 INDIGO study shows sustained response and clinically-relevant growth accelerations in PFIC2 responders Data from Phase 2b ICONIC study show profound and durable improvements in itch severity and serum bile acids in children with Alagille

Mirum Pharmaceuticals to Present Phase 2 Clinical Results of Maralixibat in Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis at the International Liver Congress

March 27, 2019

Maralixibat shows reductions in pruritus and serum bile acids in 48 week analysis of ICONIC Phase 2b study in Alagille syndrome patients Long-term analysis of INDIGO study of maralixibat shows sustained response and growth improvements in progressive familial intrahepatic cholestasis type two

Events

More events are coming soon.

Investor Relations

Investor Relations

Corporate Profile

Header Menu